SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      ICMR Serosurveillance Group
    • Source:
      Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101613665 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2214-109X (Electronic) Linking ISSN: 2214109X NLM ISO Abbreviation: Lancet Glob Health Subsets: MEDLINE
    • Publication Information:
      Original Publication: [England] : Elsevier Ltd. 2013-
    • Subject Terms:
      Antibodies, Viral/*blood ; COVID-19/*epidemiology ; SARS-CoV-2/*immunology; Adolescent ; Adult ; COVID-19/blood ; Child ; Cross-Sectional Studies ; Female ; Humans ; Immunoglobulin G ; India/epidemiology ; Male ; Middle Aged ; Occupations ; Prevalence ; Seroepidemiologic Studies
    • Abstract:
      Background: The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done in May-June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34-1·13). We aimed to assess the more recent nationwide seroprevalence in the general population in India.
      Methods: We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey. Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded. Participants were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. 3-5 mL of venous blood was collected from each participant and blood samples were tested using the Abbott SARS-CoV-2 IgG assay. Seroprevalence was estimated after applying the sampling weights and adjusting for clustering and assay characteristics. We randomly selected one adult serum sample from each household to compare the seroprevalence among adults between the two serosurveys.
      Findings: Between Aug 18 and Sept 20, 2020, we enrolled and collected serum samples from 29 082 individuals from 15 613 households. The weighted and adjusted seroprevalence of SARS-CoV-2 IgG antibodies in individuals aged 10 years or older was 6·6% (95% CI 5·8-7·4). Among 15 084 randomly selected adults (one per household), the weighted and adjusted seroprevalence was 7·1% (6·2-8·2). Seroprevalence was similar across age groups, sexes, and occupations. Seroprevalence was highest in urban slum areas followed by urban non-slum and rural areas. We estimated a cumulative 74·3 million infections in the country by Aug 18, 2020, with 26-32 infections for every reported COVID-19 case.
      Interpretation: Approximately one in 15 individuals aged 10 years or older in India had SARS-CoV-2 infection by Aug 18, 2020. The adult seroprevalence increased approximately tenfold between May and August, 2020. Lower infection-to-case ratio in August than in May reflects a substantial increase in testing across the country.
      Funding: Indian Council of Medical Research.
      (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
    • References:
      Science. 2020 Aug 14;369(6505):846-849. (PMID: 32576668)
      Int J Epidemiol. 2021 Feb 22;:. (PMID: 33615345)
      Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424)
      Immunity. 2020 Nov 17;53(5):925-933.e4. (PMID: 33129373)
      Emerg Infect Dis. 2003 Aug;9(8):991-4. (PMID: 12967499)
      Lancet Infect Dis. 2021 Apr;21(4):e69-e70. (PMID: 32679085)
      Nat Rev Immunol. 2020 Sep;20(9):519. (PMID: 32686754)
      Int J Infect Dis. 2020 Dec;101:138-148. (PMID: 33007452)
      Euro Surveill. 2020 Aug;25(31):. (PMID: 32762796)
      Int J Epidemiol. 1996 Dec;25(6):1107-16. (PMID: 9027513)
      Lancet Glob Health. 2020 Nov;8(11):e1390-e1398. (PMID: 32979314)
      Lancet. 2020 Aug 22;396(10250):535-544. (PMID: 32645347)
      Lancet Glob Health. 2021 Feb;9(2):e110-e111. (PMID: 33197394)
      N Engl J Med. 2020 Oct 29;383(18):1724-1734. (PMID: 32871063)
      Cell. 2020 Oct 1;183(1):158-168.e14. (PMID: 32979941)
      Lancet. 2020 Aug 1;396(10247):313-319. (PMID: 32534626)
      Bull World Health Organ. 2021 Jan 1;99(1):19-33F. (PMID: 33716331)
      Nat Med. 2020 Jun;26(6):845-848. (PMID: 32350462)
      Ann Intern Med. 2020 Sep 1;173(5):362-367. (PMID: 32491919)
      Nature. 2020 Jun;582(7813):467-468. (PMID: 32546810)
      Indian J Med Res. 2020 Jul & Aug;152(1 & 2):48-60. (PMID: 32952144)
    • Grant Information:
      001 International WHO_ World Health Organization
    • Contributed Indexing:
      Investigator: R Andhalkar; A Chaudhury; H Deval; S Dhatrak; RR Gupta; E Ilayaperumal; B Jagjeevan; RC Jha; K Kiran; NN Krishnan; A Kumar; VV Kumar; K Nagbhushanam; A Nimmathota; AK Pandey; HS Pawar; KS Rathore; A Robinson; HB Singh; VC Wilson; A Yadav; R Yadav; T Karunakaran; J Pradhan; T Sivakumar; A Jose; K Kalaiyarasi; S Dasgupta; R Anusha; T Anand; GR Babu; H Chauhan; T Dikid; RR Gangakhedkar; S Kant; S Kulkarni; JP Muliyil; RM Pandey; S Sarkar; A Shrivastava; SK Singh; S Zodpey; A Das; P Das; S Dutta; R Kant; K Narain; S Narasimhaiah; S Pati; S Patil; H Rajkumar; T Ramarao; K Sarkar; S Singh; GS Toteja; K Zaman
    • Accession Number:
      0 (Antibodies, Viral)
      0 (Immunoglobulin G)
    • Publication Date:
      Date Created: 20210130 Date Completed: 20210225 Latest Revision: 20210416
    • Publication Date:
      20221213
    • Accession Number:
      PMC7906675
    • Accession Number:
      10.1016/S2214-109X(20)30544-1
    • Accession Number:
      33515512